Andrew Koustenis

1.8k citations
31 papers · 1.0k indexed · 1 hit paper · h-index 12
Topics
Lung Cancer Treatments and Mutations (13 papers)Lung Cancer Research Studies (12 papers)Advanced Breast Cancer Therapies (9 papers)
Partner nations
United StatesSpainFrance

In The Last Decade

Andrew Koustenis

30 papers receiving 1.0k citations

Hit Papers

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CD...20172026202020232017100200300400

Peers

Andrew Koustenis
Comparison fields: 5 of 58
  • Pulmonary and Respiratory Medicine 758
  • Oncology 686
  • Cancer Research 204
  • Genetics 151
  • Molecular Biology 138
Replace Adriana C. H. van Engen–van Grunsven with:
Adriana C. H. van Engen–van Grunsven Netherlands
Xianxin Qiu China
Jashbhai K. Patel United States
L. Pronk Netherlands
Diane Goltz Germany
Navesh Sharma United States
Janice Patterson United States
Tyler P. Robin United States
Claudia Le United States
Andrew Koustenis relative to Adriana C. H. van Engen–van Grunsven Netherlands Adriana C. H. van Engen–van Grunsven's profile →
Citations per field
00.5×6.0×
Adriana C. H. van Engen–van Grunsven · 1×
Citations per year

Countries citing papers authored by Andrew Koustenis

Since Specialization
Citations

This map shows the geographic impact of Andrew Koustenis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Koustenis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Koustenis more than expected).

Fields of papers citing papers by Andrew Koustenis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Koustenis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Koustenis. The network helps show where Andrew Koustenis may publish in the future.

Co-authorship network of co-authors of Andrew Koustenis

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Koustenis. A scholar is included among the top collaborators of Andrew Koustenis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Koustenis. Andrew Koustenis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 1
3 16
4 9
5 2
6 3
7
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancerbreakdown →
490
8 1
9 6
10 1
11 134
12 4
13 52
14 44
15 120
16 12
17 27
18 26
19 28
20 5

About Andrew Koustenis

Andrew Koustenis is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine, having authored 31 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (12 papers) and Advanced Breast Cancer Therapies (9 papers). The work is most often cited by research in Oncology (686 citations), Pulmonary and Respiratory Medicine (758 citations) and Genetics (151 citations). Andrew Koustenis has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Sara M. Tolaney, Maura N. Dickler, Véronique Dièras, Javier Cortés, Debra A. Patt, José Baselga, Hans Wildiers, Hope S. Rugo, Martin Frenzel and Clifford A. Hudis. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026